Blue Arrow Capital Management’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Blue Arrow Capital Management’s Portfolio GEVA Stock Details GEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-151	Closed	-$14K	–	233
2014 Q4	$14K	Buy	+151	New	+$11.9K	﹤0.01%	185
2014 Q2	–	Sell	-6,000	Closed	-$498K	–	200
2014 Q1	$498K	Buy	+6,000	New	+$555K	0.08%	94

Other funds holding GEVA

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Blue Arrow Capital Management's GEVA Position: Q1 2015 in Review

Blue Arrow Capital Management sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q1 2015, closing a stake of 151 shares — an estimated $14K sold.

Blue Arrow Capital Management first reported a position in GEVA in Q1 2014 and held it in 2 quarters. The position peaked at $498K in Q1 2014. 130 funds tracked by Wall St. Rank hold GEVA as of Q1 2015.

Blue Arrow Capital Management reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q1 2015 after selling out during the quarter.
Blue Arrow Capital Management sold 151 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q1 2015, an estimated $14K.
Blue Arrow Capital Management first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q1 2014 and held it in 2 quarters.
Blue Arrow Capital Management's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $498K in Q1 2014.
130 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q1 2015.

Based on Blue Arrow Capital Management's 13F filing for Q1 2015, filed 15 May 2015.